Caryn Weir-Wiggins

Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas

Derick R. Peterson, J. Friedberg, R. Fisher, 2016, Leukemia & lymphoma.

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

John D. Roberts, S. Grant, H. Sankala, 2017, Leukemia & lymphoma.

Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

John D. Roberts, D. Coppola, S. Grant, 2014, Clinical Cancer Research.

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update

John D. Roberts, G. Garcia-Manero, S. Grant, 2011 .

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

John D. Roberts, S. Grant, H. Sankala, 2014 .

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

John D. Roberts, M. Raffeld, Hui-Yi Lin, 2015, Clinical Cancer Research.

A Phase II Trial of AZD 6244 ( Selumetinib , ARRY-142886 ) , an Oral MEK 1 / 2 Inhibitor , in Relapsed / Refractory Multiple Myeloma

John D. Roberts, M. Raffeld, Hui-Yi Lin, 2015 .